T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST

Nat Rev Clin Oncol. 2010 Feb;7(2):116-9. doi: 10.1038/nrclinonc.2009.218.


Background: A 71-year-old male patient was diagnosed as having a KIT-positive gastrointestinal stromal tumor located at the gastric antrum. With no signs of distant metastasis, the patient primarily underwent gastric surgery with antrectomy and Billroth-I-reconstruction. Owing to tumor size and mitotic index, the patient was considered at high risk of tumor relapse and thus was entered into a clinical trial to receive adjuvant imatinib treatment. 4 months after initiation of imatinib treatment, the patient presented with several newly discovered subcutaneous and intra-abdominal tumor lesions. Imatinib treatment had been tolerated well until then.

Investigations: Physical examination, blood tests, biopsies of the subcutaneous tumor lesions, tumor morphology and immunohistochemistry, PCR for the T-cell receptor gamma genes, sequential CT and PET-CT.

Diagnosis: Monoclonal T-cell lymphoproliferative disorder, potentially induced by imatinib.

Management: Imatinib was stopped, after which the tumor lesions spontaneously regressed and, eventually, complete remission was achieved.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Benzamides
  • Chemotherapy, Adjuvant
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Gastrointestinal Stromal Tumors / surgery
  • Humans
  • Imatinib Mesylate
  • Male
  • Piperazines / adverse effects*
  • Pyrimidines / adverse effects*
  • T-Lymphocytes / drug effects*
  • Treatment Outcome


  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate